TY - JOUR
TI - Safety and efficacy of global intracoronary administration of cardiosphere-derived cells or conditioned medium immediately after coronary reperfusion in rats
AU - Vakrou, S.
AU - Nana, M.A.
AU - Nanas, I.A.
AU - Nana-Leventaki, E.
AU - Bonios, M.
AU - Kapelios, C.
AU - Nanas, J.
JO - Ελληνική καρδιολογική επιθεώρηση
PY - 2020
VL - 61
TODO - 4
SP - 256-261
PB - Hellenic Cardiological Society
SN - 1011-7970
TODO - 10.1016/j.hjc.2019.03.001
TODO - genomic DNA;  glyceryl trinitrate;  heparin;  isoflurane;  low density lipoprotein cholesterol;  meloxicam;  mercaptoethanol;  microRNA;  penicillin derivative;  streptomycin;  thioflavine;  transcription factor Sox2, animal experiment;  animal model;  animal tissue;  Article;  cardiosphere derived cell;  coronary artery;  coronary reperfusion;  DNA isolation;  electroporation;  fetal calf serum;  gene expression;  heart function;  heart muscle biopsy;  heart protection;  heart rate;  intracoronary drug administration;  male;  nonhuman;  pluripotent stem cell;  rat;  real time polymerase chain reaction;  thoracotomy;  transthoracic echocardiography;  animal;  cardiac muscle;  conditioned medium;  disease model;  female;  heart infarction;  heart muscle reperfusion, Animals;  Culture Media, Conditioned;  Disease Models, Animal;  Female;  Male;  Myocardial Infarction;  Myocardial Reperfusion;  Myocardium;  Rats
TODO - Objective: Cardiosphere-derived cells (CDCs) have been shown to reduce infarct size after myocardial infarction (MI). In the present study we investigated the safety and efficacy of global intracoronary administration (GIA) of CDCs or CDC-conditioned medium (CM) immediately after reperfusion in a rat model of ischemia-reperfusion. Methods: CDCs were grown from myocardial biopsies obtained from male Wistar Kyoto rats (WKY). Female WKY rats underwent MI for 45minutes, followed by reperfusion for 1hour. Infarcted rats were randomized to receive GIA of CDCs (CDC group), CM (CM group) or vehicle (control group) immediately after the onset of reperfusion. Cell retention was quantified by PCR for the male specific SRY gene; area at risk (AR) and no reflow area (NR) were measured by histopathology. Cardiac function was evaluated by echocardiography at 1 and 2 months post-MI. Results: Cell retention at 1hour after GIA was 25.1% ±5.1. The myocardial AR and NR (measured at 1 hour post-reperfusion) were similar between groups [AR: 28.8% ±7.4 of LV mass in control vs 27.2% ±8 in CM vs 27% ±7 in CDCs group. NR: 7.0% ±3.3 in control vs 7.3% ±3.8 in CM vs 7.1% ±3.6 in CDCs]. One and 2 months post-MI, systolic function and LV volumes did not differ between control and CM groups. Conclusion: Intracoronary administration of CDCs during the acute phase of MI, at the beginning of reperfusion, does not aggravate microvascular obstruction and results in high cell retention. Delivery of CM in the acute phase of MI did not confer long-term cardiac functional benefits. © 2019 Hellenic Society of Cardiology
ER -